Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Mar 7;129(9):2456-7.
doi: 10.1021/ja0693587. Epub 2007 Feb 7.

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide

Affiliations

Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide

Federico Bernal et al. J Am Chem Soc. .

Erratum in

  • J Am Chem Soc. 2007 Apr 25;129(16):5298
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Synthesis, sequence, and biochemical analysis of SAH-p53 peptides. (A) Non-natural amino acids were synthesized as described and cross-linked by ruthenium-catalyzed ring-closing olefin metathesis. (B) SAH-p53 compounds were generated by stapling the p5314-29 sequence at the indicated positions. Charge, α-helicity, hDM2 binding affinity, cell permeability, and impact on cell viability are indicated for each compound. (C, E) Circular dichroism spectra revealed enhancement of α-helicity for SAH-p53 compounds. (D, F) Fluorescence polarization assays using FITC-peptides and hDM217-125 demonstrated subnanomolar hDM2-binding affinities for select SAH-p53 peptides. Note: UAH-p53-8 is the “unstapled” form of SAH-p53-8.
Figure 2.
Figure 2.
SAH-p53-8 reactivates the p53 transcriptional pathway. The hDM2 overexpressing SJSA-1 cells were exposed to the indicated peptides, and Western analyses for p53, hDM2, and p21 were performed at 8–30 h of treatment.
Figure 3.
Figure 3.
Reactivation of apoptosis in SAH-p53-8-treated SJSA-1 cells. SAH-p53-8 demonstrated specific, dose-dependent cytotoxicity and apoptosis induction as measured by (A) CellTiter-Glo (Promega) and (B) Caspase-3 activation assays (Oncogene).

Similar articles

Cited by

References

    1. Kastan MB; Onyekwere O; Sidransky D; Vogelstein B; Craig RW Cancer Res. 1991, 51, 6304–6311. - PubMed
    1. Wu X; Bayle JH; Olson D; Levine AJ Genes Dev. 1993, 7, 1126–1132. - PubMed
    2. Yonish-Rouach E; Resnftzky D; Lotem J; Sachs L; Kimchi A; Oren M Nature 1991, 352, 345–347. - PubMed
    3. Momand J; Zambetti GP; Olson DC; George D; Levine AJ Cell 1992, 69, 1237. - PubMed
    1. Levine AJ; Hu W; Feng Z Cell Death Differ. 2006, 13, 1027. - PubMed
    2. Honda R; Tanaka H; Yasuda H FEBS Lett. 1997, 420, 25. - PubMed
    3. Tao W; Levine AJ Proc. Nat. Acad. Sci. U.S.A 1999, 96, 3077–3080. - PMC - PubMed
    1. Li M; Brooks CL; Wu-Baer F; Chen D; Baer R; Gu W Science 2003, 302, 1972–1975. - PubMed
    1. Hollstein M; Sidransky D; Vogelstein B; Harris CC Science 1991, 253, 49–53. - PubMed

Publication types

MeSH terms